Inventiva (IVA) Total Non-Current Liabilities (2018 - 2025)
Inventiva's (IVA) quarterly Total Non-Current Liabilities came in at $233.6 million in Q4 2025, up 108.4% year-on-year from $112.1 million in Q4 2024, and down 99.84% quarter-over-quarter from $146.5 billion in Q2 2025.
Inventiva (IVA) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Inventiva's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $233.6 million for Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 108.4% year-over-year to $233.6 million in Q4 2025; TTM through Dec 2025 was $233.6 million, a 108.4% increase from a year earlier, with the FY2025 full-year figure at $233.6 million, up 108.4% from the prior year.
- Total Non-Current Liabilities fell to $233.6 million in Q4 2025 per IVA's latest filing, from $146.5 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $146.5 billion in Q2 2025 and bottomed at $11.7 million in Q4 2021.
- The 5-year median for Total Non-Current Liabilities is $55.3 million (2023), against an average of $18.1 billion.
- Across the five-year window, Total Non-Current Liabilities fell 28.62% in 2021 and jumped 93614.43% in 2022, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $11.7 million in 2021, then jumped by 245.99% to $40.6 million in 2022, then surged by 36.19% to $55.3 million in 2023, then jumped by 102.53% to $112.1 million in 2024, then surged by 108.4% to $233.6 million in 2025.
- Per Business Quant, the three latest IVA Total Non-Current Liabilities figures stand at $233.6 million (Q4 2025), $146.5 billion (Q2 2025), and $112.1 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - | 233.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 233.57 Mn |
| Jun 30, 2025 | 146.48 Bn |
| Dec 31, 2024 | 112.08 Mn |
| Dec 31, 2023 | 55.34 Mn |
| Dec 31, 2022 | 40.63 Mn |
| Jun 30, 2022 | 15.60 Bn |
| Dec 31, 2021 | 11.74 Mn |
| Jun 30, 2021 | 16.65 Mn |
| Mar 31, 2021 | 16.76 Mn |
| Dec 31, 2020 | 16.45 Mn |
| Jun 30, 2020 | 1.97 Mn |
| Dec 31, 2019 | 1.89 Mn |
| Dec 31, 2018 | 3.58 Mn |